MedFacts
MedFacts uses artificial intelligence to speed up finding and designing new antibiotics. It relies on proprietary platforms MedGEN, MedBIO, MedTOX, and MedDOCK to model biology and test candidates virtually. The company positions itself as an AI drug discovery firm focused on antibiotic-resistant infections and collaborates with pharmaceutical developers. Its technology spans AI, cheminformatics, and computational biology to streamline screening, optimization, and prediction. The market focus is scalable drug discovery for urgent needs in antibacterial resistance.
MedFacts
MedFacts uses artificial intelligence to speed up finding and designing new antibiotics. It relies on proprietary platforms MedGEN, MedBIO, MedTOX, and MedDOCK to model biology and test candidates virtually. The company positions itself as an AI drug discovery firm focused on antibiotic-resistant infections and collaborates with pharmaceutical developers. Its technology spans AI, cheminformatics, and computational biology to streamline screening, optimization, and prediction. The market focus is scalable drug discovery for urgent needs in antibacterial resistance.